About this Course
UConn has developed web-based continuing pharmacy education activities to enhance the practice of pharmacists and assist pharmacists in making sound clinical decisions to affect the outcome of anticoagulation therapy for the patients they serve. There are a total of 17.25 hours of CPE credit available. Successful completion of these 17.25 hours (13 activities) or equivalent training will prepare the pharmacist for the Anticoagulation Traineeship, which described below in the Additional Information Box.
The activities below are available separately for $17/hr or as a bundle price of $199 for all 13 activities (17.25 hours). These are the pre-requisites for the anticoagulation traineeship. Any pharmacist who wishes to increase their knowledge of anticoagulation may take any of the programs below.
When you are ready to submit quiz answers, go to the Blue "Take Test/Evaluation" Button.
Target Audience
Pharmacists who are interested in making sound clinical decisions to affect the outcome of anticoagulation therapy for the patients they serve.
This activity is NOT accredited for technicians.
Pharmacist Learning Objectives
At the completion of this activity, the participant will be able to:
|
|
Release Date
Released: 07/15/2025
Expires: 07/15/2028
Course Fee
$8.50
ACPE UAN
ACPE #0009-0000-25-047-H01-P
Session Code
25AC47-KWX83
Accreditation Hours
0.5 hour of CE
Bundle Options
If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.
You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.
Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(17.25 hours of CE) $199.00
In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.
Additional Information
Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT
The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.
Accreditation Statement
The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of credit for the online activity ACPE #0009-0000-25-047-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.
Grant Funding
There is no grant funding for this activity.
Requirements for Successful Completion
To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.
Type in your NABP ID, DOB and the session code for the activity. You were sent the session code in your confirmation email.
Faculty
Angela Su, PharmD
Educational Outreach Coordinator
University of Connecticut
Storrs, CT
Faculty Disclosure
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
Dr. Su has no relationship with an ineligible company and therefore has nothing to disclose.
Disclaimer
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Program Content
Program Handouts
Post Test Evaluation
View Questions for Heparin, Low Molecular Weight Heparin and Fondaparinux Questions
1. Ty is admitted to your hospital for community-acquired pneumonia. You notice that he is a candidate for VTE prophylaxis. He is a 70-year-old male, 5’5”, and 75 kg (165 lbs). Labs include INR 1.1, BUN 30, and SCr 2.5. What is the most appropriate recommendation?
a. Enoxaparin 40 mg SC daily
b. Heparin IV per thromboembolic protocol
c. Enoxaparin 30 mg SC daily
2. Which of the following is an approved indication for low molecular weight heparin?
a. Treatment of venous thromboembolism
b. Anticoagulation in patients with a history of HIT
c. Prevention in patients with renal insufficiency
3. You are at a lecture on LMWH and fondaparinux and the speaker says that these two medications have three things in common. He says, “First, with both medications, you would not dose adjust or avoid using them in patients with impaired renal function. Second, you must order anti-Xa testing on Days 2 and 4 of therapy. Third, with both, active major bleeding is a contraindication for use.” What should you do?
a. Raise your hand and challenge his statement on patients with impaired renal function
b. Raise your hand and challenge his statement on ordering anti-Xa testing
c. Do nothing; these great clinical pearls will make it easier for you to screen patients.
4. A nurse calls, concerned about a patient on heparin for a new blood clot. The patient is going for hemodialysis today. They are unsure of how dialysis will affect the patient's heparin therapy. What would you recommend?
a. Recommend an additional bolus heparin dose immediately following dialysis
b. Ask the prescriber to change to LMWH because heparin is contraindicated in dialysis
c. Say hemodialysis will not affect heparin levels so continue therapy as prescribed
5. A patient who is on LMWH is experiencing a major bleed and needs surgery. The surgeon wants to give protamine. What should you tell her?
a. Protamine will completely reverse LMWH’s anti-factor IIa and Xa effects
b. Give 1 mg protamine per mg of LMWH and repeat every 8 hours for 4 additional doses
c. Anti-factor IIa and Xa activities may return up to three hours after you give the dose
6. Why should prescribers never use enoxaparin sodium injection from multiple dose vials in neonates, infants or pregnant women?
a. No studies have established the appropriate dose
b. It contains benzyl alcohol preservative
c. It causes gastrointestinal colic-like symptoms
7. Which of the following is a contraindication for fondaparinux?
a. Body weight greater than 150 kg (330 lbs)
b. Bacterial endocarditis
c. Sever hepatic impairment
8. A patient accidentally injects her dalteparin twice and the prescriber is frantic and wants to handle the overdose quickly. What is the appropriate dose of protamine?
a. 1 mg protamine for every 1 mg dalteparin administered
b. 1 mg protamine for every 100 anti-Xa units of dalteparin given
c. 1 mg protamine for every 1 mg dalteparin in excess of the normal dose
9. What are the most serious symptoms of protamine overdose?
a. Severe hypotensive fatal reactions, often resembling anaphylaxis
b. Excessive bleeding unresponsive to further protamine doses
c. Epidural or spinal hematomas causing long-term/permanent paralysis
10. Which of the following is a boxed warning on the LMWHs and fondaparinux?
a. Severe hypotensive fatal reactions, often resembling anaphylaxis
b. Excessive bleeding unresponsive to intervention with protamine
c. Epidural or spinal hematomas with neuraxial anesthesia or spinal puncture
Additional Courses Available for Anticoagulation
Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour
Anticoagulation Management Pearls - 1.5 hour
Clinical Overview of Direct Oral Anticoagulants– 1.25 hour
Laboratory Monitoring of Anticoagulation – 2 hour
Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours
Developing an Anticoagulation Clinic – 1.0 hour
Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour
Risk Management in Anticoagulation – 1 hour
A Practical Approach to Perioperative Oral Anticoagulation Management – 2 hour
Management of Hypercoagulable States – 1.5 hour
Challenging Topics in Anticoagulation – 2 hour
Available Strategies to Reverse Anticoagulation Medications - 2 hour
Drug Interaction Cases with Anticoagulation Therapy – 1 hour